Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ABCZY NASDAQ:GMAB OTCMKTS:GNMSF NYSE:RDY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCZYAbcam$0.00$11.26▼$19.73$3.98B1.294,712 shs5,400 shsGMABGenmab A/S$22.95+1.2%$21.75$17.24▼$27.94$14.71B0.951.44 million shs613,873 shsGNMSFGenmab A/S$216.31$215.60$170.00▼$282.06$14.29B0.93522 shs100 shsRDYDr. Reddy's Laboratories$14.16-0.7%$14.81$12.26▼$16.85$11.82B0.291.87 million shs1.17 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCZYAbcam0.00%0.00%0.00%0.00%0.00%GMABGenmab A/S+3.66%+5.39%+5.64%+15.37%-14.68%GNMSFGenmab A/S0.00%0.00%+0.63%+14.57%-15.87%RDYDr. Reddy's Laboratories+2.55%+6.78%-2.16%-0.90%-14.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCZYAbcamN/AN/AN/AN/AN/AN/AN/AN/AGMABGenmab A/S3.9882 of 5 stars3.34.00.00.03.90.03.1GNMSFGenmab A/S0.8556 of 5 stars0.03.00.00.02.70.01.3RDYDr. Reddy's Laboratories3.0841 of 5 stars2.54.01.70.03.30.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCZYAbcam 0.00N/AN/AN/AGMABGenmab A/S 2.64Moderate Buy$37.8064.74% UpsideGNMSFGenmab A/S 0.00N/AN/AN/ARDYDr. Reddy's Laboratories 3.00Buy$16.9519.75% UpsideCurrent Analyst Ratings BreakdownLatest ABCZY, GNMSF, GMAB, and RDY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025GMABGenmab A/STruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$45.00 ➝ $46.006/5/2025RDYDr. Reddy's LaboratoriesHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/5/2025RDYDr. Reddy's LaboratoriesHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$14.44 ➝ $16.90(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCZYAbcam$336.37M0.00N/AN/AN/ANaNGMABGenmab A/S$3.26B4.51$1.59 per share14.42$8.26 per share2.78GNMSFGenmab A/S$3.12B4.58$15.19 per share14.24$80.24 per share2.70RDYDr. Reddy's Laboratories$334.26B0.04$1.05 per share13.47$4.94 per share2.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCZYAbcamN/AN/A0.000.00N/AN/AN/AN/AN/AGMABGenmab A/S$1.14B$1.9911.5312.896.4237.53%21.03%16.98%N/AGNMSFGenmab A/S$1.14B$19.9210.86∞N/A37.53%21.03%16.98%N/ARDYDr. Reddy's Laboratories$663M$0.6621.4517.265.6016.99%17.25%11.63%N/ALatest ABCZY, GNMSF, GMAB, and RDY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025GMABGenmab A/S$0.39$0.54+$0.15$0.54$5.77 billion$925.00 million8/7/2025Q2 2025GNMSFGenmab A/S$3.99$5.42+$1.43$5.42$949.06 million$925.00 million7/23/2025Q1 25/26RDYDr. Reddy's Laboratories$0.18$0.20+$0.02$0.20$88.27 billion$988.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCZYAbcam$0.070.36%N/AN/AN/AGMABGenmab A/SN/AN/AN/AN/AN/AGNMSFGenmab A/SN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.070.49%N/A10.61%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCZYAbcamN/AN/AN/AGMABGenmab A/SN/A6.226.20GNMSFGenmab A/SN/A6.226.20RDYDr. Reddy's Laboratories0.011.891.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCZYAbcamN/AGMABGenmab A/S7.07%GNMSFGenmab A/SN/ARDYDr. Reddy's Laboratories3.85%Insider OwnershipCompanyInsider OwnershipABCZYAbcamN/AGMABGenmab A/S1.54%GNMSFGenmab A/S1.54%RDYDr. Reddy's Laboratories2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCZYAbcam1,750205.08 millionN/ANot OptionableGMABGenmab A/S2,682641.54 million631.66 millionOptionableGNMSFGenmab A/S2,68266.07 million65.06 millionNot OptionableRDYDr. Reddy's Laboratories27,811834.90 million818.20 millionOptionableABCZY, GNMSF, GMAB, and RDY HeadlinesRecent News About These CompaniesTriglav Skladi D.O.O. Takes $857,000 Position in Dr. Reddy's Laboratories Ltd (NYSE:RDY)August 14 at 7:16 AM | marketbeat.comAIA Group Ltd Sells 101,293 Shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY)August 14 at 5:25 AM | marketbeat.comQ2 EPS Forecast for Dr. Reddy's Laboratories Cut by AnalystAugust 14 at 2:29 AM | americanbankingnews.comDr. Reddy’s Laboratories to Engage in Virtual Investor Conference on August 21, 2025August 13 at 11:22 AM | msn.comNatixis Advisors LLC Trims Stock Position in Dr. Reddy's Laboratories Ltd (NYSE:RDY)August 13 at 3:15 AM | marketbeat.comDr. Reddy’s Subsidiary Imperial Dissolved Following NCLT ApprovalAugust 12 at 8:20 PM | theglobeandmail.comCritical Review: Dr. Reddy's Laboratories (NYSE:RDY) vs. Targeted Medical Pharma (OTCMKTS:TRGM)August 11 at 2:13 AM | americanbankingnews.comDr. Reddy's Laboratories (NYSE:RDY) vs. Aspen Pharmacare (OTCMKTS:APNHY) Head-To-Head SurveyAugust 10, 2025 | americanbankingnews.comXY Capital Ltd Sells 47,520 Shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY)August 9, 2025 | marketbeat.comUS Bancorp DE Has $2.15 Million Holdings in Dr. Reddy's Laboratories Ltd (NYSE:RDY)August 9, 2025 | marketbeat.comPinpoint Asset Management Ltd Reduces Position in Dr. Reddy's Laboratories Ltd (NYSE:RDY)August 8, 2025 | marketbeat.comEnvestnet Asset Management Inc. Cuts Stock Holdings in Dr. Reddy's Laboratories Ltd (NYSE:RDY)August 7, 2025 | marketbeat.comDr. Reddy's: Needs To Invest $0.95 To Produce $1 Of New RevenuesAugust 4, 2025 | seekingalpha.comDr. Reddy's Laboratories Ltd (NYSE:RDY) Shares Sold by Allianz Asset Management GmbHJuly 29, 2025 | marketbeat.comDr. Reddy’s Laboratories Releases Q1 2025 Earnings Call AudioJuly 25, 2025 | theglobeandmail.comDr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost RevenuesJuly 24, 2025 | zacks.comDr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call TranscriptJuly 23, 2025 | seekingalpha.comDr. Reddy's Laboratories Limited 2026 Q1 - Results - Earnings Call PresentationJuly 23, 2025 | seekingalpha.comDr. Reddy's Q1FY26 Financial ResultsJuly 23, 2025 | businesswire.comDr. Reddy’s to launch generic semaglutide in 87 countries: BloombergJuly 23, 2025 | msn.comDr. Reddy’s Laboratories (RDY) and Alvotech Enter Into a Collaboration and License AgreementJuly 23, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABCZY, GNMSF, GMAB, and RDY Company DescriptionsAbcam OTCMKTS:ABCZYAbcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Germany, the United Kingdom, and internationally. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. The company also offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc has partnership with Cancer Research UK for the development and commercialization of novel custom antibodies to support the acceleration of cancer research. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.Genmab A/S NASDAQ:GMAB$22.94 +0.28 (+1.21%) As of 03:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Genmab A/S OTCMKTS:GNMSF$216.31 0.00 (0.00%) As of 08/12/2025Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Dr. Reddy's Laboratories NYSE:RDY$14.16 -0.11 (-0.74%) As of 03:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cisco Systems: The Only AI Stock Income Investors Need to Own Brinker Serves Up Earnings Beat, Sidesteps Cost Pressures CAVA’s Honeymoon Ends With a 16% Stock Drop Rigetti Stock: A Long-Term Quantum Play Facing Short-Term Tests 5 Stocks Insiders Are Selling That Analysts Say Buy CoreWeave Pulls Back Into a Screaming Buy Amazon’s Bears Have Raised the White Flag—Get Excited Rocket Lab Scores Analyst Upgrades, Finalizes Geost Takeover Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access